3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Medullary
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Interventions
Everolimus
15
surufatinib
7
lutetium Lu 177 dotatate
6
lanreotide
6
amino-acid, glucose, and electrolyte solution
5
Octreotide
5
Sunitinib
4
Data Collection
4
pasireotide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
tislelizumab
2
pembrolizumab
2
fosbretabulin
2
arginyllysine
2
Temozolomide
2
Paclitaxel
2
PM 01183
2
Irinotecan
2
Carboplatin
2
64Cu-SARTATE
2
3-Iodobenzylguanidine
2
toripalimab
1
telotristat ethyl
1
taxane
1
repotrectinib
1
pralsetinib
1
pelcitoclax
1
liposomal doxorubicin
1
gadoteridol
1
gadoterate meglumine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroendocrine Tumors
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA